CJC-1295 no DAC / Hexarelin Blend
CJC + Hexarelin
CJC-1295 no DAC / Hexarelin Blend is a pre-mixed growth hormone secretagogue combination that pairs Modified GRF(1-29) with the most potent GHRP available. Hexarelin (Examorelin) produces the highest raw GH release per dose of any ghrelin receptor agonist, making this blend the strongest GH-releasing peptide combination on the market. It is designed for short, intensive cycles where maximum GH output is the priority.
Starting dose. 100mcg CJC + 100mcg Hexarelin per injection
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
This blend delivers the most potent dual-receptor GH stimulation available through injectable secretagogues:
CJC-1295 no DAC (Mod GRF 1-29)
Binds GHRH receptors on pituitary somatotrophs, activating the cAMP/PKA signaling cascade to prime and release stored GH granules. The four amino acid substitutions protect against DPP-IV degradation, extending the half-life to approximately 30 minutes. Produces acute GH pulses preserving natural pulsatile patterns.
Hexarelin
Binds GHS-R1a (ghrelin receptor) with the highest efficacy of any GHRP, triggering GH release through the PLC/IP3/PKC pathway. Hexarelin's strong receptor activation produces the most potent GH pulses but also causes the fastest receptor desensitization (tachyphylaxis), limiting effective cycle length to 4-8 weeks. It also suppresses somatostatin release more aggressively than other GHRPs.
Cardioprotective Mechanism
Uniquely among GHRPs, Hexarelin binds CD36 scavenger receptors on cardiomyocytes, activating cardioprotective signaling pathways independent of GH release. This includes improved cardiac contractility, reduced fibrosis, and protection against ischemia-reperfusion injury.
Synergistic Amplification
The GHRH signal (CJC) and the strongest GHRP signal (Hexarelin) converge through independent intracellular pathways, producing GH pulses 5-8x above baseline in responsive individuals. This exceeds the output of CJC/Ipa or CJC/GHRP-2 combinations.
Hormonal Trade-offs
Hexarelin elevates cortisol and prolactin more than GHRP-2, which elevates more than Ipamorelin. These elevations are dose-dependent and generally manageable at standard doses but require monitoring during cycles.
What to expect
Days 1-7: Strong flushing and tingling post-injection (Hexarelin's potent GHS-R1a activation). Improved sleep quality with deeper slow-wave phases. Moderate appetite increase. Possible mild water retention. The flush intensity is a useful biomarker - when it diminishes, the receptor is desensitizing.
Weeks 2-4: Peak GH output period. Body composition changes visible faster than with milder blends. Skin quality improving. Recovery from training dramatically enhanced. Fat loss and lean mass changes measurable. This is the most productive window of the cycle.
Weeks 4-8: Receptor desensitization begins in most individuals. Flush response weakens. GH output gradually declines toward baseline. End the cycle when the flush response is notably reduced. Take a 4-8 week break before starting another Hexarelin cycle. Consider transitioning to CJC/Ipa for maintenance between Hexarelin cycles.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Quick-start dose/route: 100 mcg CJC + 100 mcg Hexarelin per injection, SubQ, 1-2x daily. GAP — UNSUPPORTED EXACT BLEND. Searches for `"CJC-1295" AND hexarelin`, the exact blend name, and both components with subcutaneous dosing found no abstract administering this fixed blend. Standalone Hexarelin PMIDs 7957536, 8762732, and 7852535 and long-acting CJC-1295 PMID 16352683 cannot be transferred to the no-DAC fixed blend.
Mechanism: dual GHRH/GHS-R1a signaling plus Hexarelin/CD36 cardioprotection. GAP — UNSUPPORTED EXACT BLEND. No checked abstract tested the page’s combined mechanism in this pre-mixed formulation; component mechanisms do not establish blend synergy, a 5-8x GH pulse, or direct cardiac effects of the blend.
Primary safety: cortisol/prolactin elevation and rapid receptor desensitization during 4-8 week use. GAP — UNSUPPORTED EXACT BLEND. No checked abstract established these safety claims for the fixed combination, displayed route, and regimen.
The honest take
Produces the highest GH release of any injectable secretagogue combination
Supported by human data. Hexarelin produces the largest GH pulse of any GHRP, and dual GHRH+GHRP stimulation is synergistic. However, this potency comes with faster receptor desensitization and more hormonal side effects than milder combinations.
Supported by human cardiac studies and animal models. CD36 receptor binding on cardiomyocytes is a well-characterized mechanism unique to Hexarelin among GHRPs. Clinical relevance for healthy individuals using short peptide cycles is less established.
Plausible based on human GH stimulation data from individual components. The combined synergistic output has not been precisely quantified in controlled trials for this specific blend ratio.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Side effects & safety
Commonly reported
- Intense flushing and warmth post-injection (stronger than other GHRPs)
- Tingling, head rush, or dizziness immediately after injection
- Moderate appetite stimulation (between Ipamorelin and GHRP-6)
- Water retention in first 1-2 weeks
- Vivid dreams and altered sleep patterns
Less common & notes
- Hexarelin elevates cortisol and prolactin more than other GHRPs.
- At doses above 200mcg, cortisol elevation may cause post-injection anxiety or irritability.
- Elevated prolactin can cause nipple sensitivity or mild gynecomastia in susceptible individuals during extended use - this is one reason cycles should be kept to 4-8 weeks.
- Some users experience post-injection lethargy from the strong GH pulse.
- Receptor desensitization (tachyphylaxis) is the primary limitation - extending cycles beyond 8 weeks produces diminishing returns and delays recovery of receptor sensitivity.
Pharmacokinetics
CJC-1295 no DAC: ~30 min; Hexarelin: ~70 min. Combined GH pulse duration: 1.5-2.5 hours.
CJC: 15-30 min; Hexarelin: 15-20 min. Peak synergistic GH release at ~20-30 min post-injection.
CJC cleared within 2-3 hours. Hexarelin cleared within 4-5 hours. GH pulse elevation returns to baseline by 3-4 hours.
SubQ: ~95-100% for both components. Oral: not viable (peptide degradation in GI tract). Hexarelin has also been studied via intranasal route with lower bioavailability.
GH pulse lasts 1.5-2.5 hours (slightly longer than CJC/Ipa due to Hexarelin potency). Downstream IGF-1 elevation persists 12-20 hours. Hexarelin CD36 cardiac effects have a separate, longer duration independent of GH pulse.
Enzymatic degradation by peptidases. CJC modifications provide DPP-IV resistance. Hexarelin cleared by renal and hepatic peptidases.
Storage. Store lyophilized vial at room temperature or refrigerated. After reconstitution with bacteriostatic water, store refrigerated at 2-8 degrees C. Use within 28-30 days of reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if solution becomes cloudy or contains particulate matter.
Regulatory status
Not FDA-approved as a combination product. Available through compounding pharmacies with prescription. CJC-1295 no DAC (Mod GRF 1-29) has published human pharmacokinetic data. Hexarelin (Examorelin) has been studied in multiple human clinical trials for GH release and cardiac applications, and is approved in some countries for diagnostic use. Pre-mixed blends are a compounding pharmacy product. Classified as research peptides in most jurisdictions. All use is experimental and off-label.
Put it to work
Calculate, log & track
Open CJC-1295 no DAC / Hexarelin Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open CJC-1295 no DAC / Hexarelin Blend in the app →Go deeper
The guide & community
The complete CJC-1295 no DAC / Hexarelin Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗